Virtual Library

Start Your Search

Genki Takahashi

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-02 - Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer (ID 12980)

      12:00 - 13:30  |  Author(s): Genki Takahashi

      • Abstract
      • Slides


      Various types of immunothrapies have been extensively developed in advanced non-small cell lung cancer (NSCLC). Although median survival times have been getting very long in a certain population, complete remission (CR) is still uncommon. This study aimed to elucidate features of CR cases with advanced NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      From our hospital database, 1,699 patients, registered as having lung cancer between August 2004 and April 2011, were examined. Those with stage III or IV histologically or cytologically confirmed NSCLC, whose treatment included chemotherapy, were retrospectively evaluated on Feb 13, 2017. CR, for the purposes of this study, was defined as a sustained CR at the five-year follow-up without treatment for one year, and features of CR patients were compared with those of long-surviving patients whose overall survival time (OS) exceeded 3 years.

      4c3880bb027f159e801041b1021e88e8 Result

      There were 279 stage IV and 164 stage III patients. OS of 51 (18.3%) and 37 (22.6%) patients with stage IV and III were over 3 years, respectively. Five and 12 patients with stage IV and III, respectively, showed CR. The tale effects were observed in Stage III and IV advanced NSCLC mainly by chemotherapies without immunocheckpoint inhibitors. In stage IV, primary tumor diameters in the CR patients were shorter than those in the 3 OS < 5 patients, and metastatic numbers in the CR patients were fewer than those in the 3 OS < 5 patients. In stage III, there were no differences in primary tumor diameters and metastatic numbers among the 3 OS < 5, the 5 ≤ OS with existence of tumor, and the CR (5 ≤ OS without tumor) groups.

      8eea62084ca7e541d918e823422bd82e Conclusion

      This study demonstrated that CR might be possible in certain patients with small primary tumors and fewer metastases even in advanced NSCLC by employing combinations of various treatment modalities.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.